A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer

Exclusion Criteria

• •1. The subject is currently participating in any other clinical trial,Or has received or is receiving other investigational agents within 4 weeks prior to the first dose of study drug.
• •2. Use of immunomodulatory drugs within 2 weeks prior to the first use of study drug.
• •3. Patients with active infection and currently requiring systemic treatment. active pulmonary tuberculosis (TB), receiving anti-tuberculosis treatment or Received anti-tuberculosis treatment within 6 months before screening.
• •4. Patients with clinically uncontrollable pleural effusion, pericardial effusion or ascites, and those requiring repeated drainage or medical intervention.
• •5. The patient has a Medical history of immunodeficiency, including HIV antibody positive.
• •6. Active hepatitis B or active hepatitis C.
• •7. Women during pregnancy or lactation.
• •8. History of mental and/or psychiatric illness (impairing understanding or giving informed consent), drug abuse, alcoholism, or drug addiction.
• •9. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.